Organoid Models

HUB Organoid Technology offers the most relevant in vitro preclinical models for screening the efficacy of drugs against various human diseases, such as cancer or cystic fibrosis. The unique capacity of HUB Organoids™ to recapitulate characteristics of the organ they originate from opens up new possibilities for research and drug development. Moreover, the long-term expansion of HUB Organoid cultures and access to a healthy counterpart provide a unique platform for drug discovery and development.

Cystic Fibrosis Models Description

Cystic Fibrosis (CF) is an inherited disorder that causes severe damage to the lungs, digestive system and other organs in the body. People with CF carry a defect in the CFTR gene causing bodily secretions to become sticky and thick, impeding the functionality of the affected organs.

Worldwide, about 70,000 to 100,000 people have CF. A major problem in treating CF is the diversity of the genetic defect. More than 2000 different mutations have been identified in CF patients, and while only 12 mutations are represented in 50% of the CF population, more than 1900 mutations are distributed in the other 50%.

In an assay developed by its founders, HUB has demonstrated that we can determine a patient’s clinical response (or lack of response) based directly on an organoid of that patient. In addition, HUB has generated a CF biobank which consists of more than 400 HUB Organoid cultures derived from rectal biopsies of CF patients and which represents more than 100 mutations, both common and rare. Using this CF biobank, the effectiveness of (novel) compounds on the CF population or on specific mutations can be accurately determined in vitro (Forskolin-Induced Swelling (FIS) assay)

Cancer Models Description

HUB Organoids can be generated directly from biopsies or resections of cancer with very high efficiency. This enables us to generate a genetically stable, heterogeneous, and patient-relevant biobank of all carcinoma indications (table 1). In addition, HUB organoids can be generated from both normal and malignant tissues of patients. Using the platform, highly relevant and very efficient drug screening and development of oncological drugs can be performed in an in vitro model that represents the heterogenic mutational landscape present in cancer patients.

HUB offers a unique collection of well-characterized cancer organoid models for industry’s in-house use, for drug testing services at HUB or through its partners.

Immuno-Oncology Models Description

HUB has established a new HUB Organoid model to co-culture patient-derived tumour organoids and immune cells, either innate or engineered, for the screening of IO compounds, or engineered T-cells.


Toxicology Models Description

The most important reason we have preclinical assessment of newly developed drugs is to predict their safety and efficacy in humans. HUB has established organoid cultures from preclinical animal models such as rats, dogs, mini pigs and monkeys. These HUB Organoid cultures are generated from several parts of the gastrointestinal tract and faithfully recapitulate the original tissue response to external stimuli. Furthermore, HUB has validated the use of HUB Organoid cultures derived from human donors as a liver toxicology model.

HUB toxicology organoid models represent a unique in vitro platform for studying toxicity, absorption, metabolism and the pharmacokinetics of compounds, drug safety and efficacy allowing decision making at an early stage of drug development.


Infectious Disease Models Description

HUB’s healthy organoids represent all components of the corresponding tissue and are suited to the study of infectious diseases affecting specialized human cell types, such as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) on human lung and intestine organoids, Respiratory Syncytial Virus (RSV) on human lung organoids or Hepatitis B Virus (HBV) on human liver organoids.

Other Indications Description

HUB and various industry partners collaborate to continuously develop new HUB Organoid models. We are currently setting up models for COPD, and other (genetic) lung diseases, IBD, and genetic liver diseases. Upon request we can discuss to see if an organ or disease can be represented and developed as an organoid model.